F2, coagulation factor II, thrombin, 2147

N. diseases: 490; N. variants: 42
Disease: Hemophilia, NOS ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0684275
Disease: Hemophilia, NOS
Hemophilia, NOS 		0.100 Biomarker disease BEFREE Nevertheless, prothrombin had not decreased in both WT and hemophilia. 31006077 2019
CUI: C0684275
Disease: Hemophilia, NOS
Hemophilia, NOS 		0.100 AlteredExpression disease BEFREE Besides the well-known bypassing agents (i.e. activated prothrombin complex concentrate and recombinant activated factor VII) used to treat or prevent bleeding in haemophilia patients with inhibitors, there is growing interest in newer haemostatic therapies that are not based on the replacement of the deficient FVIII. 31246563 2019
CUI: C0684275
Disease: Hemophilia, NOS
Hemophilia, NOS 		0.100 AlteredExpression disease BEFREE Besides the well-known bypassing agents (i.e. activated prothrombin complex concentrate and recombinant activated factor VII) used to treat or prevent bleeding in haemophilia patients with inhibitors, there is growing interest in a new class of therapeutic agents which act by enhancing coagulation (i.e. emicizumab) or inhibiting anticoagulant pathways (i.e. fitusiran and concizumab). 29517971 2018
CUI: C0684275
Disease: Hemophilia, NOS
Hemophilia, NOS 		0.100 Biomarker disease BEFREE Prothrombin complex concentrates (PCCs), designed to treat bleeding in hemophilia patients, are safely and efficiently used off label for hemorrhage after bypass. 28648539 2017
CUI: C0684275
Disease: Hemophilia, NOS
Hemophilia, NOS 		0.100 Biomarker disease BEFREE To evaluate the effect of FII on haemophilia recombinant human (rh) FII (MEDI8111) or plasma-derived human FII (pdhFII) was given as single doses to anaesthetized haemophilia A and B mice 3 min before tail transection and rhFVIII or rhFIX was used for comparison. 26635073 2016
CUI: C0684275
Disease: Hemophilia, NOS
Hemophilia, NOS 		0.100 AlteredExpression disease BEFREE According to a World Federation of Hemophilia survey, 223 HA and 6 HB patients in Iran have developed inhibitor and have been mainly managed by recombinant FVII (rFVIIa) and activated prothrombin-complex concentrate. 26914731 2016
CUI: C0684275
Disease: Hemophilia, NOS
Hemophilia, NOS 		0.100 AlteredExpression disease BEFREE Recombinant factor VIIa and activated prothrombin complex concentrates are similarly effective in populations of patients with hemophilia and inhibitors; however, individuals may show a better response to one agent over another. 25428222 2014
CUI: C0684275
Disease: Hemophilia, NOS
Hemophilia, NOS 		0.100 Biomarker disease BEFREE Understanding the mechanism of action of normal hemostasis and how the bypassing agents recombinant activated factor VII (rFVIIa; NovoSeven) and plasma-derived activated prothrombin complex concentrate (Factor Eight Inhibitor Bypassing Agent [FEIBA]) control abnormal bleeding is imperative for healthcare professionals who treat patients with hemophilia and other bleeding disorders. 22632160 2012
CUI: C0684275
Disease: Hemophilia, NOS
Hemophilia, NOS 		0.100 Biomarker disease BEFREE Haemophilia is diagnosed from prothrombin time, activated partial thromboplastin time, and FIX levels. 12747585 2003
CUI: C0684275
Disease: Hemophilia, NOS
Hemophilia, NOS 		0.100 GeneticVariation disease BEFREE The first symptomatic bleeding leading to diagnosis of severe hemophilia (< 1%) occurred with a median (range) age of 1.6 years (0.5-7.1) in children carrying defects within the protein C pathway or the PT gene mutation compared with non-carriers of prothrombotic risk factors (0.9 years (0.1-4.0; p = 0.01). 11246535 2001
CUI: C0684275
Disease: Hemophilia, NOS
Hemophilia, NOS 		0.100 Biomarker disease BEFREE The original patient with prothrombin Denver had a severe haemophilia-like bleeding disorder treated with weekly prophylactic factor replacement. 10651742 2000
CUI: C0684275
Disease: Hemophilia, NOS
Hemophilia, NOS 		0.100 Biomarker disease BEFREE Results from 22 International Haemophilia Training Centres (IHTCs) provide target values for the prothrombin time (PT), activated partial thromboplastin time (APTT), factor VIII:C, IX:C and von Willebrand factor assays, against which the performance of haemophilia centres (HCs) in developing countries can be assessed. 9873890 1998
CUI: C0684275
Disease: Hemophilia, NOS
Hemophilia, NOS 		0.100 Biomarker disease BEFREE The presence of factor IX Hilo in patient plasma was responsible for the patient having a very long ox brain prothrombin time characteristic of severe hemophilia Bm. 2713493 1989
CUI: C0684275
Disease: Hemophilia, NOS
Hemophilia, NOS 		0.100 Biomarker disease BEFREE This is the first report of the molecular defect in a hemophilia Bm patient with a markedly prolonged ox brain prothrombin time. 2563663 1989